 |
|
|
| |
Efficacy and Safety of Elbasvir/Grazoprevir in Treatment-Naive
Participants With Chronic Hepatitis C Virus Genotype 1, 4, or 6
Infection (C-CORAL): A Phase 3 Randomized, International Trial
|
| |
| |
Reported by Jules Levin
EASL 2017 April 19-23 Amsterdam Netherlands
Wei L1*; Zhdanov K2*; Burnevich E3; Sheen I-S4; Heo J5; Nguyen VK6; Tanwandee T7; Cheng P-N8; Kim DY9; Tak WY10; Kizhlo S11; Duan Z12; Peng C-Y13; Liang LW14; Evans B14; Hanna G14; Barr E14; Robertson M14; Ingravallo P14; Talwani R14; George J15
*Co-first authors contributed equally to this poster
1Peking University People's Hospital, Beijing, China; 2Military Medical Academy n.a. S.M. Kirov, St. Petersburg, Russia; 3Moscow Sechenov Medical Academy, Moscow, Russia; 4Linkou Medical Center, Chang Gung Memorial Hospital, Taipei Taiwan; 5Pusan National University Hospital, Pusan, South Korea;
6National Hospital of Tropical Diseases, Hanoi, Vietnam; 7Siriraj Hospital, Bangkok, Thailand; 8National Cheng Kung University Hospital, Tainan, Taiwan; 9Severance Hospital, Seoul, South Korea; 10Kyungpook
National University Hospital, Daegu, South Korea; 11City Center for AIDS and Infectious Diseases Treatment and Prophylaxis, St. Petersburg, Russia; 12Beijing Youan Hospital, Capital Medical University, Beijing, China; 13China Medical University Hospital, Taichung City, Taiwan; 14Merck & Co., Inc., Kenilworth, NJ, USA; 15Storr Liver Centre, Westmead Institute for Medical Research, University of Sydney, Sydney, NSW, Australia
|
| |
|
|
|
|
|
